| Variant title |
Title for parts I and II: Unsustainable drug prices : testimony from the CEOs |
| Variant title |
Title for part III: Unsustainable drug prices : testimony from AbbVie CEO Richard Gonzalez |
| General note | "One Hundred Sixteenth Congress, second session"--Pts. 1 and 2. |
| General note | "One Hundred Seventeenth Congress, first session"--Pt. 3. |
| General note | Access ID (govinfo, pt. 1): CHRG-116hhrg41982. |
| General note | Access ID (govinfo, pt. 2): CHRG-116hhrg41983. |
| General note | "Serial no. 116-122"--Pt. 1 |
| General note | "Serial no. 116-123"--Pt. 2 |
| General note | "Serial no. 117-22"--Pt. 3 |
| General note | "September 30, 2020"--Pt. 1. |
| General note | "October 1, 2020"--Pt. 2. |
| General note | "May 18, 2021"--Pt. 3. |
| General note | GPO Cataloging Record Distribution Program (CRDP). |
| Performer |
Hearing witnesses (pt. 1): Mr. Mark Alles, Former Chairman of the Board and Chief Executive Officer, Celgene Corporation; Dr. Giovanni Caforio, Chairman of the Board and Chief Executive Officer, Bristol Myers Squibb Company; Mr. Kare Schultz, President and Chief Executive Officer, Teva Pharmaceutical Industries Ltd. |
| Performer |
Hearing witnesses (pt. 2): Mr. Robert Bradway, Chairman and Chief Executive Officer, Amgen Inc.; Mr. Mark Trudeau, President and Chief Executive Officer, Mallinckrodt Pharmaceuticals; Mr. Thomas Kendris, U.S. Country President, Novartis AG. |
| Date/time/place of a event note | Date of hearing (pt. 1): 2020-09-30. |
| Date/time/place of a event note | Date of hearing (pt. 2): 2020-10-01. |
| Source of description | Description based on online resource; title from PDF title page (govinfo, viewed July 6, 2021). |
| Issued in other form | Print version: United States. Congress. House. Committee on Oversight and Reform. Unsustainable drug prices |
| Issued in other form | Microfiche version: United States. Congress. House. Committee on Oversight and Reform. Unsustainable drug prices |
| Genre/form | Legislative hearings. |
| Genre/form | Legislative hearings. |
| Standard identifier# |
41-982 (GPO jacket number ; pt. 1) |
| Standard identifier# |
41-983 (GPO jacket number ; pt. 2) |
| Standard identifier# |
44-685 (GPO jacket number ; pt. 3) |
| Technical rpt number | Serial no. 116-122 (United States. Congress. House. Committee on Oversight and Reform) |
| Technical rpt number | Serial no. 116-123 (United States. Congress. House. Committee on Oversight and Reform) |
| Technical rpt number | Serial no. 117-22 (United States. Congress. House. Committee on Oversight and Reform) |
| GPO item number | 1016-C (online) |
| Govt. docs number |
Y 4.OV 2:116-122 |
| Govt. docs number |
Y 4.OV 2:116-123 |
| Govt. docs number |
Y 4.OV 2:117-22 |
